- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 279/02 - 1,2-ThiazinesHydrogenated 1,2-thiazines
Patent holdings for IPC class C07D 279/02
Total number of patents in this class: 94
10-year publication summary
|
7
|
7
|
2
|
8
|
2
|
11
|
2
|
7
|
6
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vandria SA | 17 |
7 |
| F. Hoffmann-La Roche AG | 7838 |
6 |
| Genentech, Inc. | 4101 |
6 |
| Amgen Inc. | 4418 |
6 |
| Mochida Pharmaceutical Co., Ltd. | 341 |
4 |
| Centre National de La Recherche Scientifique | 11010 |
3 |
| Resverlogix Corp. | 54 |
3 |
| Sunshine Lake Pharma Co., Ltd. | 626 |
3 |
| Universita Degli Studi di Perugia | 47 |
3 |
| Universita degli Studi di Trento | 76 |
3 |
| Universite de Poitiers | 191 |
3 |
| Sorbonne Universite | 1391 |
3 |
| Samsung Display Co., Ltd. | 38544 |
2 |
| Janssen Pharmaceutica N.V. | 3175 |
2 |
| Merck Patent GmbH | 5725 |
2 |
| Riken | 1715 |
2 |
| Sierra Sciences, LLC | 8 |
2 |
| Wakunaga Pharmaceutical Co., Ltd. | 41 |
2 |
| Kojin Therapeutics, Inc. | 18 |
2 |
| Fondazione Telethon ETS | 103 |
2 |
| Other owners | 28 |